Answers are grounded in this paper and cite their sources.
Prehospital thrombolysis with Tenecteplase was not associated with improved survival or ROSC in OHCA and may be linked to worse outcomes. These findings highlight a lack of sustained benefit associated with empiric thrombolysis based on suspected thromboembolic cause in OHCA, and raise questions about its routine prehospital use without definitive diagnosis.
No takes yet. Share an insight, caveat, or question.
Jaquet et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: